ChristopherJonForlenzaMD

Pediatric Hematology & Oncology • New York, NY

Physician

Overview of Dr. Forlenza

Dr. Christopher Forlenza is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from New York University Grossman School of Medicine and has been in practice 9 years. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 135 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 20 publications and over 500 citings.

Office
1275 York Ave
New York, NY 10065
Book by Phone+1(424) 296-4902

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 2008 - 2011
New York University School of MedicineClass of 2008

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma Start of enrollment: 2015 Mar 19
Active, not recruiting
Phase 3
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Start of enrollment: 2019 Dec 27
Completed
Phase 2, Phase 3

Publications & Presentations

PubMed

57 citations
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma
Christopher J. Forlenza, Jeanette E. Boudreau, Junting Zheng, Jean-Benoît Le Luduec, Elizabeth Chamberlain
Journal of Clinical Oncology. 2016-09-27
11 citations
Combination Brentuximab Vedotin and Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma.
Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael Absalon, Sharon M. Castellino
Blood Advances. 2021-09-24
24 citations
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic L...
Sanam Shahid, Kavitha Ramaswamy, Jessica Flynn, Audrey Mauguen, Karlo Perica
Transplantation and Cellular Therapy. 2021-11-28

Journal Articles

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC, Jounal of Clinical Oncology, 7/20/2016

Abstracts/Posters

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
Christopher J. Forlenza, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

St. Baldrick's Fellow GrantSt. Baldrick's Foundation2014–2017

Professional Memberships

Children's Oncology Group
Member